Back

Left atrial total emptying fraction is the main predictor of atrial fibrillation in patients with hypertrophic cardiomyopathy

11 December 2025 (08:00 - 15:30)
Organised by: Logo
Congress Presentation Part of: What is new in hypertrophic cardiomyopathy Myocardial Disease EACVI Premium Access EACVI 2025 European Association of Cardiovascular Imaging (EACVI)

About the speaker

Photo
Doctor Ioana Bianca Cergan

Institute of Cardiovascular Diseases Prof. C.C. Iliescu, Bucharest (Romania)

6 More presentations in this session

Presentation thumbnail
Innovative markers of left atrial remodeling in the prediction of exercise capacity in sarcomeric hypertrophic cardiomyopathy
Mr A. Melot (Rennes, FR)
Abstract Slides
Presentation thumbnail
Echocardiographic parameters of left ventricular diastolic dysfunction, left atrial volumes and left atrial function improves in obstructive hypertrophic cardiomyopathy during mavacamten treatment
Doctor A. Kormanyos (Szeged, HU)
Abstract Slides
Presentation thumbnail
Echocardiographic drag effect index predicts response to mavacamten in obstructive hypertrophic cardiomyopathy
Doctor J. Ha (Seoul, KR) Associate Professor I. Cho (Seoul, KR)
Abstract Slides
Presentation thumbnail
Right-sided cardiac echocardiographic parameters show no major change during 3-months mavacamten treatment in obstructive hypertrophic cardiomyopathy
Doctor N. Schvartz (Szeged, HU)
Abstract Slides
Presentation thumbnail
Echocardiographic changes with mavacamten in patients with obstructive hypertrophic cardiomyopathy: early experience from a referral center
Doctor L. Videla (Barcelona, ES)
Abstract Slides

Access the full session

Session thumbnail
What is new in hypertrophic cardiomyopathy

The Event

Event poster

EACVI 2025

11 December - 13 December 2025
You may be interested in
thumbnail
Congress Presentation
Echocardiography as first-line technique in suspected cardiac amyloidosis
thumbnail
Congress Presentation
What is the best imaging method to assess myocardial viability? 
thumbnail
Congress Presentation
Dilated cardiomyopathy

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources